NCT03433001 · OUTCOME

Percentage of Participants Who Continue to Receive Treatment at 12 Months and 24 Months After Start of Treatment

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone · Source last updated 2023-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of Participants
Interval / dispersion: 95% Confidence Interval
Time frame: 12 months and 24 months

Analysis population: Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.

Groups in this outcome

Ixazomib + Lenalidomide + Dexamethasone

Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Ixazomib + Lenalidomide + Dexamethasone	295

Reported measurements

Month 12

Values in Percentage of Participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Ixazomib + Lenalidomide + Dexamethasone	40.0	Not reported	34.4	45.8	Not reported

Month 24

Values in Percentage of Participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Ixazomib + Lenalidomide + Dexamethasone	21.7	Not reported	17.1	26.8	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
34.4
upper Limit
45.8
value
40.0
title
Month 12
categories
measurements
group Id
OG000
lower Limit
17.1
upper Limit
26.8
value
21.7
title
Month 24

denoms

counts
group Id
OG000
value
295
units
Participants

dispersion Type

95% Confidence Interval

groups

description
Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.
id
OG000
title
Ixazomib + Lenalidomide + Dexamethasone

param Type

NUMBER

population Description

Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.

reporting Status

POSTED

time Frame

12 months and 24 months

title

Percentage of Participants Who Continue to Receive Treatment at 12 Months and 24 Months After Start of Treatment

type

SECONDARY

unit Of Measure

Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice